Minerva Neurosciences (United States)

company in Waltham, United States

NERV Nasdaq ISIN US6033802058 SEC CIK 1598646
Follow Minerva Neurosciences (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
EPS, diluted $1.94 +638.9% vs same quarter last year
Operating cash flow −$8.1M −179.5% vs same quarter last year
Operating income −$9.4M −231.7% vs same quarter last year
Net income by quarter
−$4.3M
−$3.8M
−$3.3M
−$2.7M
−$283.7M
−$125.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$293.4M
FY24$0$1.4M
FY23$0−$30M
FY22$0−$32.1M
FY21$0−$49.9M
FY20$0$1.9M
FY19$0−$72.2M
FY18$0−$50.2M
FY17$0−$31.5M
FY16-−$31M
FY15-−$27.1M
FY14-−$56.9M
FY13-−$3.3M
FY12--
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0$10MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22−$24.7M
FY21-
FY20-
FY19-
FY18-
FY17$3M
FY16-
FY15-
FY14−$36M
FY13−$2.2M
FY12-